Casting-type calcifications with invasion and high-grade XXXX : a more aggressive disease?

@entity1 @entity172 @entity3821 @entity0 @entity1420 @entity5 @entity262 @entity513
HYPOTHESIS: @entity1 with @entity0 who have casting-type microcalcifications associated with multifocal invasion and extensive @entity3821 ( @entity3821 ) form a subset of @entity1 with a poor prognosis. Our study aims to identify the mammographic and pathologic features of this group. DESIGN: @entity1 with casting-type microcalcifications, multifocal invasion, and extensive @entity3821 were identified from our @entity5 board registry. Mammographic features, @entity5 characteristics, treatment, and survival rates were evaluated. Invasive @entity5 were limited to 14 mm or smaller. SETTING: University medical teaching hospital and @entity0 specialty clinic. RESULTS: Of the 984 @entity1 with @entity0 treated at our center, 15 @entity1 were identified who had extensive casting-type calcifications and @entity3821 . Twelve of these @entity1 also had multifocal invasive @entity0 . All had casting-type microcalcifications occupying more than 1 breast quadrant. All but 1 of the @entity1 were treated using mastectomy with sentinel node biopsy or axillary node dissection. All but 1 @entity1 had extensive grade 3 @entity3821 . Invasive @entity5 were negative for @entity172 receptor and @entity1420 receptor expression in half of the @entity1 , and 60% were positive for the HER-2-neu receptor. Positive axillary lymph nodes were found in 33% of @entity1 , and 75% received adjuvant chemotherapy. After a median follow-up period of 20.5 months (range, 6-72 months), 1 @entity1 had died and 1 had distant metastases. Of the 3 @entity1 who had @entity3821 without invasion, 1 experienced a recurrence with infiltrating @entity513 . CONCLUSIONS: In @entity1 with small multifocal @entity0 with extensive casting calcifications and @entity3821 , the incidence of positive lymph nodes was 33%, with a tendency for poor @entity5 markers. These @entity1 appear to be at substantial risk for @entity262 ; lymph node sampling and adjuvant systemic therapy are recommended.
